DB25530InvestigationalCell transplant therapies
renizgamglogene autogedtemcel is a biologic drug. renizgamglogene autogedtemcel is under investigation in clinical trial NCT05444894 (EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)).
- Also known as
- Autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/CAS12a at the HBG1 and HBG2 promoters · autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/Cas12a ribonucleoprotein (RNP) at the HBG1 and HBG2 promoters · reni-cel
- Code names
- EDIT-301
Resolves to
Compound
What you can answer from here — as of December 07, 2025
Which companies are running trials of renizgamglogene autogedtemcel, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account